5' and 3' homology arms were PCR amplified from C57BL/6 Bac clones ... 7.5 x 106 NIH3T3 cells expressing wild type or mutant ZBP1 were seeded into 15 cm ...
To include crisis-related deaths in the crisis-free quintile-specific estimates obtained from .... classification based on income can be downloaded at: https://datahelpdesk.worldbank.org/ .... 20report%202017%20child%20mortality%20final.pdf. ...... C
Dec 5, 2018 - Evidence from a migration lottery program. 2011 Food Policy. 36 1. 42186. English ...... North Kerala. 2011 Indian journal of public health. 55 2.
report of clinical diagnosis of dementia or a report of a prescription of cholinesterase inhibitor for ...... After obtaining informed consent, study eligibility was.
Sep 27, 2018 - Michelle Lane, Research Midwife; Emma Meadows, Research Midwife; Miss ... Prof Fergal Malone, Consultant Obstetrician and Gynaecologist; ...
Oct 5, 2017 - âsystemic inflammatory response syndromeâ OR âSIRSâ). IL-6 ...... SIRS OR "multiple organ dysfunction syndrome" OR MODS)) AND (PMX OR ...
Aug 28, 2018 - demographics were recorded prospectively in the electronic medical ... Endpoint definitions: For the purposes of this study, the investigators agreed to ... Event adjudication: Adjudication of events and the exact cause of death ...
Aug 24, 2016 - The analysis involved 189 different product codes over 22 regions in India, ... concentrating on the ten product codes accounting for the most.
construction, Pr 1v = 1l = E [q2 | a] for all a 2 A, meaning that the probability that ... that, with probability 1/2, reveals his underlying valuation, which is .... Figure B.1 illustrates how a downward-sloping segment for G near q1 = 0 is necessar
Alexa-. Fluor. 488 tag. Increased retinal cell apoptosis with DARC was seen in transgenic compared to age-matched controls ...... absolute Annexin uptake: Delta.
Sep 25, 2018 - http://www.who.int/tb/country/data/download/en/â (downloaded 11/01/2018). We also ..... (20,700) 32,790 (6,174). 104,500 ..... country and World Health Organization and country/territory (specified by âISO 3166-1 alpha-3.
Jayasinghe, Cathy Mcintosh, Michelle Ord, Maria Plotz, Peter Purnell, Philip ..... Llana, Michelle Dellorso, Douglas Denham, Dina Desalle, Mary Dettmer, Manu.
Sep 25, 2018 - States: Center for Vaccine Development, University of Maryland. Aga Khan ..... Enteric pathogen surveillance in a case-control study of acute diarrhoea in the town of. Kisii, Kenya. ..... Househam KC, Mann MD, Bowie MD.
These plates were incubated for 10-12 h at 37ËC; the lids were removed and the plates with culture were ...... Error bars represent standard error. .... bacteria isolates (N=8,106) from milk samples from Maasai and Arusha households ...... 151. Has
29 Oct 2018 - ... Ismail, R. L. Goldenberg, A.Altman, E. O. Ohuma, M. Purwar, I. O. Frederick, ...... Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, ...
Jihoon Kim, MDa, Joo Myung Lee, MD, MPH, PhDa, Ki Hong Choi, MDa, Tae-Min Rhee,. MDb, Doyeon Hwang, MD c, Jonghanne Park, MD, PhDd, Chul Ahn, ...
Aug 7, 2018 - assigned 'no concern' to the estimate when the confidence (black line) ...... of elementary school students at Bantul District, Yogyakarta Special.
One of his sisters had a Wilms tumor and died at 13 years of age. .... and his mother, who is also affected by MODY Type 2, carry a disease-causing variant in.
CD20 (clone L26, Dako), CD5 (clone 4C7, Novocastra), CD23 (clone 1B12, Novocastra) and SOX11. (clone MRQ-58, CellMarque) were investigated in ...
Treatment intensity at the care unit level . ... 54.2 (13.6) ... 8840 (14.4%) ... 4.8 (1.0). 4.9 (1.0). 4.9 (1.0). 5.0 (1.1). 5.1 (1.1). 63853 (24.0%). Triglycerides, mmol/l.
Supplementary Appendix Should Diabetes Mellitus be a Compelling Indication for Renin Angiotensin System Blockers? Insights from a Systematic Review and Meta-Analysis of Randomized Trials
Sripal Bangalore, MD, MHA, Robert Fakheri, MD, Bora Toklu, MD, Franz H. Messerli, MD
This appendix has been provided by the authors to give readers additional information about their work.
1
Contents Figure S1. Study selection ............................................................................................................... 3 Figure S2. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of death ............................................................................................................................................... 4 Figure S3. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of cardiovascular death ....................................................................................................................... 5 Figure S4. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of myocardial infarction ...................................................................................................................... 6 Figure S5. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of angina pectoris ................................................................................................................................ 7 Figure S6. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of stroke .............................................................................................................................................. 8 Figure S7. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of heart failure .................................................................................................................................... 9 Figure S8. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of death ............................................................................................................................................. 10 Figure S9. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of end stage renal disease................................................................................................................. 11 Figure S10. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of drug withdrawal due to adverse effects ....................................................................................... 12 Table S1. Details of Search Terms ................................................................................................ 13 Table S2. Baseline Characteristics of the Clinical Trials included in the Meta-analysis ............... 14 Table S3. RAS blockers vs. other antihypertensive agents: Sensitivity analysis excluding impaired fasting glucose cohorts ................................................................................................................. 16 References .................................................................................................................................... 17
2
Figure S1. Study selection
Records identified through database search using terms “AngiotensinConverting enzyme inhibitor”, “angiotensin receptor antagonist”, and limited to RCT, Humans (n=11120) Duplicate studies (n=2010) Records excluded on the basis of title and/or abstract (n=8545)
Full-text articles assessed for eligibility (n=565) Sample size
